Insights from the breast cancer screening trials: How screening affects the natural history of breast cancer and implications for evaluating service screening programs

Lászlõ Tabár, Amy Ming Fang Yen, Wendy Yi Ying Wu, Sam Li Sheng Chen, Sherry Yueh Hsia Chiu, Jean Ching Yuan Fann, May Mei Sheng Ku, Robert A. Smith, Stephen W. Duffy, Tony Hsiu Hsi Chen

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

It is desirable to have a strategy for evaluation of breast cancer service screening programs years before the long-term breast cancer mortality data are available. Since successful mammography screening has a significant impact on two components of the TNM (tumor size, node status, presence or absence of distant metastases) classification system, tumor size and node status, we investigated the effect of the randomized breast screening trials on incidence of advanced stage disease and on the subsequent breast cancer death rate. In the trials that achieved a 20% or greater reduction in advanced stage disease, there was an average breast cancer mortality reduction of 28% among women invited to screening (attenders and nonattenders combined). In the trials that achieved a reduction in advanced stage disease of less than 10%, there was no reduction in breast cancer mortality among women invited to screening. This study provides evidence that the average mortality reduction in all the trials underestimates the true mortality reduction, and that substantially greater breast cancer mortality reductions can be expected in screening programs that are effective in reducing advanced stage breast cancer. In addition, monitoring the incidence of advanced stage breast cancer in an ongoing screening program can provide a sensitive and early indicator of the subsequent mortality from the disease.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalBreast Journal
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Early Detection of Cancer
Breast Neoplasms
Mortality
Incidence
Mammography
Neoplasms
Breast
Neoplasm Metastasis

Keywords

  • advanced stage
  • breast cancer
  • early detection
  • mortality
  • screening

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology
  • Surgery
  • Medicine(all)

Cite this

Insights from the breast cancer screening trials : How screening affects the natural history of breast cancer and implications for evaluating service screening programs. / Tabár, Lászlõ; Yen, Amy Ming Fang; Wu, Wendy Yi Ying; Chen, Sam Li Sheng; Chiu, Sherry Yueh Hsia; Fann, Jean Ching Yuan; Ku, May Mei Sheng; Smith, Robert A.; Duffy, Stephen W.; Chen, Tony Hsiu Hsi.

In: Breast Journal, Vol. 21, No. 1, 01.01.2015, p. 13-20.

Research output: Contribution to journalArticle

Tabár, Lászlõ ; Yen, Amy Ming Fang ; Wu, Wendy Yi Ying ; Chen, Sam Li Sheng ; Chiu, Sherry Yueh Hsia ; Fann, Jean Ching Yuan ; Ku, May Mei Sheng ; Smith, Robert A. ; Duffy, Stephen W. ; Chen, Tony Hsiu Hsi. / Insights from the breast cancer screening trials : How screening affects the natural history of breast cancer and implications for evaluating service screening programs. In: Breast Journal. 2015 ; Vol. 21, No. 1. pp. 13-20.
@article{09896d7d10cc43af92a180bd9f12baf8,
title = "Insights from the breast cancer screening trials: How screening affects the natural history of breast cancer and implications for evaluating service screening programs",
abstract = "It is desirable to have a strategy for evaluation of breast cancer service screening programs years before the long-term breast cancer mortality data are available. Since successful mammography screening has a significant impact on two components of the TNM (tumor size, node status, presence or absence of distant metastases) classification system, tumor size and node status, we investigated the effect of the randomized breast screening trials on incidence of advanced stage disease and on the subsequent breast cancer death rate. In the trials that achieved a 20{\%} or greater reduction in advanced stage disease, there was an average breast cancer mortality reduction of 28{\%} among women invited to screening (attenders and nonattenders combined). In the trials that achieved a reduction in advanced stage disease of less than 10{\%}, there was no reduction in breast cancer mortality among women invited to screening. This study provides evidence that the average mortality reduction in all the trials underestimates the true mortality reduction, and that substantially greater breast cancer mortality reductions can be expected in screening programs that are effective in reducing advanced stage breast cancer. In addition, monitoring the incidence of advanced stage breast cancer in an ongoing screening program can provide a sensitive and early indicator of the subsequent mortality from the disease.",
keywords = "advanced stage, breast cancer, early detection, mortality, screening",
author = "L{\'a}szl{\~o} Tab{\'a}r and Yen, {Amy Ming Fang} and Wu, {Wendy Yi Ying} and Chen, {Sam Li Sheng} and Chiu, {Sherry Yueh Hsia} and Fann, {Jean Ching Yuan} and Ku, {May Mei Sheng} and Smith, {Robert A.} and Duffy, {Stephen W.} and Chen, {Tony Hsiu Hsi}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/tbj.12354",
language = "English",
volume = "21",
pages = "13--20",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Insights from the breast cancer screening trials

T2 - How screening affects the natural history of breast cancer and implications for evaluating service screening programs

AU - Tabár, Lászlõ

AU - Yen, Amy Ming Fang

AU - Wu, Wendy Yi Ying

AU - Chen, Sam Li Sheng

AU - Chiu, Sherry Yueh Hsia

AU - Fann, Jean Ching Yuan

AU - Ku, May Mei Sheng

AU - Smith, Robert A.

AU - Duffy, Stephen W.

AU - Chen, Tony Hsiu Hsi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - It is desirable to have a strategy for evaluation of breast cancer service screening programs years before the long-term breast cancer mortality data are available. Since successful mammography screening has a significant impact on two components of the TNM (tumor size, node status, presence or absence of distant metastases) classification system, tumor size and node status, we investigated the effect of the randomized breast screening trials on incidence of advanced stage disease and on the subsequent breast cancer death rate. In the trials that achieved a 20% or greater reduction in advanced stage disease, there was an average breast cancer mortality reduction of 28% among women invited to screening (attenders and nonattenders combined). In the trials that achieved a reduction in advanced stage disease of less than 10%, there was no reduction in breast cancer mortality among women invited to screening. This study provides evidence that the average mortality reduction in all the trials underestimates the true mortality reduction, and that substantially greater breast cancer mortality reductions can be expected in screening programs that are effective in reducing advanced stage breast cancer. In addition, monitoring the incidence of advanced stage breast cancer in an ongoing screening program can provide a sensitive and early indicator of the subsequent mortality from the disease.

AB - It is desirable to have a strategy for evaluation of breast cancer service screening programs years before the long-term breast cancer mortality data are available. Since successful mammography screening has a significant impact on two components of the TNM (tumor size, node status, presence or absence of distant metastases) classification system, tumor size and node status, we investigated the effect of the randomized breast screening trials on incidence of advanced stage disease and on the subsequent breast cancer death rate. In the trials that achieved a 20% or greater reduction in advanced stage disease, there was an average breast cancer mortality reduction of 28% among women invited to screening (attenders and nonattenders combined). In the trials that achieved a reduction in advanced stage disease of less than 10%, there was no reduction in breast cancer mortality among women invited to screening. This study provides evidence that the average mortality reduction in all the trials underestimates the true mortality reduction, and that substantially greater breast cancer mortality reductions can be expected in screening programs that are effective in reducing advanced stage breast cancer. In addition, monitoring the incidence of advanced stage breast cancer in an ongoing screening program can provide a sensitive and early indicator of the subsequent mortality from the disease.

KW - advanced stage

KW - breast cancer

KW - early detection

KW - mortality

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=84920774718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920774718&partnerID=8YFLogxK

U2 - 10.1111/tbj.12354

DO - 10.1111/tbj.12354

M3 - Article

C2 - 25413699

AN - SCOPUS:84920774718

VL - 21

SP - 13

EP - 20

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 1

ER -